Welcome to our dedicated page for Inotiv news (Ticker: NOTV), a resource for investors and traders seeking the latest updates and insights on Inotiv stock.
Inotiv, Inc. reports news as a contract research organization providing nonclinical and analytical drug discovery and development services, research models, and related products for pharmaceutical, chemical, medical device, and biomedical research customers. Its updates commonly address Discovery and Safety Assessment activity, Research Models and Services performance, quarterly and annual financial results, and business trends tied to discovery, preclinical, and translational research demand.
Company announcements also cover collaborations and technology additions such as human-relevant in vitro models, AI-assisted bioinformatics, and multi-omics analysis within Discovery & Translational Sciences. Other recurring items include conference-call schedules, operational business updates, cybersecurity incident notices, and corporate communications affecting Nasdaq-listed common stock.
Inotiv (NASDAQ: NOTV) announced it has completed its financial restructuring and emerged from Chapter 11 protection, reducing debt by approximately $326 million and significantly strengthening its capital structure. The company reports support from existing stakeholders who collectively manage more than $60 billion in assets and have provided additional capital to back Inotiv’s long-term vision and growth initiatives.
Key senior management, including President and CEO Bob Leasure, continue to lead the business, which remains focused on delivering nonclinical and analytical drug discovery and development services and research models. Inotiv also disclosed its advisor group and provided dedicated Kroll contact details and website for stakeholders seeking information on the Chapter 11 case.
Inotiv (NASDAQ: NOTV) announced that the U.S. Bankruptcy Court for the Southern District of Texas has confirmed its Chapter 11 Plan of Reorganization. With court approval in place, the company expects to emerge from Chapter 11 protection shortly with a significantly strengthened balance sheet.
According to Inotiv, the reorganization is backed by existing stakeholders, who collectively manage more than $60 billion in assets and have provided additional capital to support long-term strategic objectives. The contract research organization reports that operations and client studies are continuing as usual during this final phase of the restructuring process.
Inotiv (NASDAQ: NOTV) entered a Restructuring Support Agreement with its first lien lenders and an ad hoc noteholder group to execute a prepackaged chapter 11 recapitalization in Texas.
The plan targets about $326 million in debt reduction and includes $65 million in new financing ($40 million bridge and $25 million DIP) while maintaining normal operations.
Inotiv (NASDAQ: NOTV) disclosed a cybersecurity incident detected August 5, 2025, with unauthorized access occurring approximately August 5–8, 2025. The company said certain data may have been acquired, including sensitive personal information, and it notified affected individuals, regulators, and U.S. law enforcement.
Inotiv offered complimentary credit monitoring, launched an external investigation, and said it has taken steps to contain the incident and enhance security.
Inotiv (Nasdaq: NOTV) reported Q1 FY2026 results for the quarter ended December 31, 2025. Revenue was $120.9 million, up 0.8% year-over-year. DSA revenue rose 12.0% and DSA net awards grew ~27% year-over-year. Adjusted EBITDA was $1.8 million (1.5% of revenue).
Consolidated net loss was $28.4 million (23.5% of revenue); operating loss widened to $16.3 million. Cash totaled $12.7 million and total debt was $405.8 million. DSA backlog was $145.4 million. Management cited site exits and ongoing site optimization.
Inotiv (NASDAQ: NOTV) will report fiscal 2026 first quarter results for the period ended December 31, 2025, on Monday, February 9, 2026, before the market opens.
The company will host a conference call the same day at 8:30 a.m. Eastern Time with domestic and international dial‑in access and a live webcast. An online replay will be available in the Investors section of Inotiv's website.
Inotiv (NASDAQ: NOTV) announced on January 13, 2026 a strategic initiative to integrate LifeNet Health’s patented TruVivo® platform into its Discovery and Translational Sciences (DTS) business.
The TruVivo® system uses primary human hepatocytes with human-derived feeder cells to build physiologically relevant in vitro models intended to improve translational predictivity. Inotiv said the integration will align preclinical models more closely with human biology and enable expansion of human-relevant tissue models beyond the liver to support clients across a range of diseases.
The companies framed the collaboration as advancing new approach methodologies to accelerate development of safer, more effective therapies.
Inotiv (NASDAQ: NOTV) announced a strategic collaboration with VUGENE on December 11, 2025 to integrate VUGENE’s cloud-based AI/ML multi-omics bioinformatics platform into Inotiv’s Discovery & Translational Sciences Division.
The partnership aims to accelerate AI-assisted drug discovery by improving interpretation of epigenomic, proteomic, and other molecular datasets to better predict drug efficacy and safety in early-stage research. Inotiv said the integration will enable more efficient, data-driven decision making for client discovery programs, while VUGENE expects broader application of its computational technologies in real-world research settings.
Inotiv (Nasdaq: NOTV) reported Q4 FY2025 revenue of $138.1M (+5.9% YoY) and FY2025 revenue of $513.0M (+4.5% YoY). Q4 operating loss narrowed to $6.8M and FY operating loss improved to $30.9M (down 64.2% YoY). Adjusted EBITDA was $11.8M (8.5% of revenue) in Q4 and $34.0M (6.6%) for FY2025. DSA revenue grew 15.7% in Q4 and DSA backlog was $138.2M at Sept 30, 2025. The company sold two U.S. properties to repay term loan principal, engaged Perella Weinberg Partners to explore refinancing, and disclosed a August 2025 cybersecurity incident with potential data access under evaluation.
Inotiv (NOTV) ranked 182nd on the 2025 Deloitte Technology Fast 500™ announced Nov. 25, 2025. The company reported 448% revenue growth from fiscal year 2021 to fiscal year 2024, the measurement period for the ranking.
Inotiv said the growth reflects strategic acquisitions, the development of complementary services, and a unified, client-focused CRO model. This is Inotiv’s third consecutive year on the Fast 500 list after prior rankings of 127th (2023) and 138th (2024).